You are here
The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.
SBC: SIGMOVIR BIOSYSTEMS, INC. Topic: NIAID
DESCRIPTION provided by applicant Respiratory syncytial virus RSV is a substantial threat to human health most severely affecting three large populations infants young children and the elderly Despite the significance of RSV disease in these different populations there are no vaccines available The goal of this Phase II STTR project is to continue preclinical testing of a novel RSV vac ...STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: BIOLOGICAL ANTI-INFECTIVE MEDICINES, LLC Topic: NIAID
DESCRIPTIONprovided by applicantNational surveillance data confirm thatof Abaumannii isolates from US intensive care units are extreme drug resistanceXDRfar higher than other pathogensAt leastandcases of XDR Abaumannii infections occur annually in the US and globallyin developed countriesrespectivelyThese infections result inanddeaths and excess healthcare costs of $million and $million in the US ...STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: TRANSGENOMIC, INC. Topic: 103
DESCRIPTION provided by applicant Low level tumor associated somatic DNA mutations can have profound implications for development of metastasis prognosis choice of treatment follow up or early cancer detection Unless they are effectively detected these low level mutations can misinform patient management decisions or become missed opportunities for personalized medicine Widely used tech ...STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health